ChronicleBio retweeted
And just like that, we have our first clinical trial and pharma partnership in the works! We’re teaming up with Prolong to take the drug they developed for stroke and see if it can help our patients with ME/CFS by increasing oxygen delivery and blood flow. Thanks to the 200TB of data @chroniclebioAI has amassed, combined with our AI engine, we are identifying patients that show hypoxia so we can focus this trial on them.
This is really the promise of the company: understanding biology at such a deep level that we can match the exact right patients to the exact right drugs and massively increase the likelihood of success of trials.
Going from company creation to first trial in less than two years is pretty cool, but there’s still a lot of work to be done to prove we can improve patients’ lives. One step at a time.
Today we are announcing our first clinical trial. We're joining forces with Prolong to evaluate a potential treatment for post exertional malaise (PEM) in #MECFS.
Sanguinate is an investigational intravenous therapy designed to deliver oxygen to deprived tissues, support blood flow, and reduce inflammation. The planned multi-site Phase 2a trial will evaluate the drug in at least 40 patients with first dosing expected mid-2027.
Most trials enroll patients based on symptoms alone, but recruitment for this study will leverage ChronicleBio's proprietary endotype intelligence platform to identify patients whose disease biology suggests they may be more likely to respond.
We are excited for our partnership with Prolong and grateful for the patient community that drives everything we do.
Read More: chroniclebio.com/news/chroni…
ChronicleBio retweeted
Announcing the first of several clinical programs in the works powered by Chronicle’s AI. More validation that our AI models powered by our living data ecosystem (200TB and counting) can decode most enigmatic diseases.
It is well researched that our patient population exhibit tissue hypoxia and reduced blood flow. Prolong’s PP-007 novel MOA addresses this.
We are hopeful that bringing this innovative molecule to the right subset of patients will improve quality of life for many of the 3.3M currently suffering from ME/CFS in the US alone. We’re 18 months old and have a long way to go to realizing our vision… Bridging AI to treatments (and cures) to millions suffering… one step at a time.
businesswire.com/news/home/2…
ChronicleBio retweeted
Nothing like waking up to dozens of congrats for taking a job you did not take! While I loved my time at Meta, no, I am not going back! I’m still dealing with severe health issues and focusing all my energy on finding cures for myself and millions of patients like me. And while it’s been a hard time personally, it has also been the most meaningful mission I have ever worked on.
Replying to @ArfurGrok
Nope, fake news! Sadly still dealing with health issues and focused on finding cures through @ChronicleBioAI.
ChronicleBio retweeted
Just had my @ChronicleBioAI blood draw. My blood will now be sent off to be sequenced for RNA, proteomics, metabolomics, and DNA as part of the most comprehensive chronic illness patient biobank to date!
Being severe enough that I'm not able to leave my apartment, I highly appreciated how easy the blood draw was. The phlebotomist let himself in per my instructions and everything was done in five minutes. And he ended up being my regular guy I use through GetLabs as well!
ChronicleBio retweeted
OK. Let's answer the question. Why is what @ChronicleBioAI so completely breakthrough level data collection?
I know you probably have "testing" fatigue. We have seen some not so helpful and very expensive testing being promoted in the last few years. I have done a LOT of expensive "so-what" testing -- this is not what is going on here.
The ChronicleBio databank is different. The people running it are super experienced and very well funded. Given the expertise of this group - I think there is a good chance we are seeing the first hints of where research in these conditions will be heading in the next decade. The data has jumped the walls of the academy!
The strength and the breakthrough data collection here is that they are not picking and choosing a level of biology to focus on. The past decade has seen some awesome metabolomics, and genetics, and proteomics, and microbiome studies but they are all disjointed, from different labs, different cohorts, different subtypes, different people.
What ChronicleBio is doing is collecting ALL the data for a very well defined group of patients. They are focusing on ME, LongCovid, hEDS, MCAS, POTS, Sjogren's. They get the subtype problem.
For each person - they will be collecting about 1 BILLION data points - i.e. pieces of information - for each person.
Complete genomics, methylomics, transcriptomics, metabolomics, proteomics. Nothing like this has ever been attempted before.
This will be the biobank that will define the subgroups, tease the genetics from the environmental factors, track changes at different severity levels.
And, they come to you. Bedridden - severe - patients can get a home visit for collection.
In the past year I have seen groups charging thousands for way less than 1% of this data - for just one level of this data.
The first 250 patients are 100% FREE for the first collection and after that each collection will be $400. This is insanely cheap and if I had to guess - I would say they they are probably covering a few thousands dollars worth of testing for each person. The 400$ likely covers the logistics of the collection - all the assay's are paid by ChronicleBio.
The only thing that bums me out is that they are not in Canada and not International. I would literally give a toe to get this testing.
This one is different. I promise.
I would 100% be doing this if it was available in Canada. Please check out chroniclebio.com/biobank
ChronicleBio retweeted
Well deserved! We are so excited about working with @ChronicleBioAI Everyone has been helpful, curious, collaborative and working hard to move this field forward. @tessfalor and I (Isabel) have been so impressed by the responsiveness and care through #innovationinn & beyond.
Thanks @Forbes for featuring the great work we’re doing @ChronicleBioAI.
There are exactly 0 FDA-approved therapies for the hundreds of millions of people suffering from diseases like POTS, Long COVID, MECFS or hEDS. We created ChronicleBio to change this.
By building the deepest dataset on these conditions and leveraging AI, we will understand what the biology behind the symptoms is. From there, we can map the right drugs to the right patients.
ChronicleBio retweeted
When I decided to leave my academic postdoc, I was nervous. If I stayed in the complex chronic illness space (EDS, POTS, ME/CFS), would my next team understand what it's like to live with these conditions? How much hope patients place in research, and how vulnerable that leaves them?
At @ChronicleBioAI I didn't have to wonder. Our founders get it, and that's what I'm most proud of about being here. I'm grateful to be doing this with people who want answers as badly as our community does.
Sufferers of complex, chronic diseases like POTS and long COVID-19 often spend years searching for relief. This former OpenAI exec started ChronicleBio to find treatments using AI and lots of biological data.
Read more: forbes.com/sites/amyfeldman/…
📸: Joel Saget/AFP via Getty Images
ChronicleBio retweeted
Thanks @Forbes for featuring the great work we’re doing @ChronicleBioAI.
There are exactly 0 FDA-approved therapies for the hundreds of millions of people suffering from diseases like POTS, Long COVID, MECFS or hEDS. We created ChronicleBio to change this.
By building the deepest dataset on these conditions and leveraging AI, we will understand what the biology behind the symptoms is. From there, we can map the right drugs to the right patients.
Sufferers of complex, chronic diseases like POTS and long COVID-19 often spend years searching for relief. This former OpenAI exec started ChronicleBio to find treatments using AI and lots of biological data.
Read more: forbes.com/sites/amyfeldman/…
📸: Joel Saget/AFP via Getty Images
ChronicleBio retweeted
Thanks @Forbes for sitting down me and my co-founders, @fidjissimo and @rohit0logy to capture the @ChronicleBioAI story.
Our living data ecosystem has generated more than 200TB+ of data (and counting) enabling our AI models to decode the most enigmatic diseases we face today.
We have already identified multiple targetable endotypes, confirming the heterogeneity of these diseases is very real and reinforcing that the status quo approaches simply will not work.
We are now on an executing on an asset strategy to bring the right therapies to the right patients as quickly as possible.
TL;DR we’re firing on all cylinders… and we’re hiring
forbes.com/sites/amyfeldman/…
ChronicleBio retweeted
Your illness isn't waiting on a test to be real. The test is waiting on science to catch up. It's why I'm proud to be a part of the work at @ChronicleBioAI and fighting to find the answers for people who've been told for far too long their experience is "normal".
ChronicleBio retweeted
I disagree with Dario on most things, but this is spot on: “At this point, saying that AI will cure cancer is more a cliché than it is inspiring, and most people think it is deceptive. The thing that will work is actually curing cancer.”
The thing that frustrates me is that some people often draw a straight line from smarter models → cures, without acknowledging how much infrastructure is missing in between. We’ve still got a lot of work to do, people.
The regulatory bottleneck gets a lot of attention. But the bigger bottleneck may be that in many places, we’re lacking the right biological data. AI can’t reason its way to cures if we haven’t generated the data required to understand the disease in the first place.
Ironically, that’s why I’m most bullish on AI making dramatic progress in cancer first: decades of investment have produced extraordinary datasets across genomics, pathology, imaging, clinical outcomes, and more.
For complex chronic diseases, much of that infrastructure simply doesn’t exist yet. The good news is that many companies (including @ChronicleBioAI) are racing to build it.
But model intelligence and biological infrastructure are going to have to scale together. I really do believe AI can cure all diseases but only if we build the infrastructure to translate intelligence into cures at the same pace that models improve (which is a high bar!). Otherwise, we risk having superintelligent AI with an incomplete picture of human biology, and delay that promise by years.
ChronicleBio retweeted
Chronic Illness @ChronicleBioAI : US adults 18+ can join a longitudinal mobile collection study with up to 3 blood draws and multi-omics research reports. The initial collection is free for the first 250 participants; later cohorts pay $400/collection. connect.chroniclebio.com/sig…
ChronicleBio retweeted
Heads up to ME/CFS researchers:
Our @RenegadeRes team just collected 482 plasma, serum, and whole blood samples before, during, and after PEM.
The majority are being set aside for specific companies to analyze, like @amaticahealth, @ChronicleBioAI, @AldenScientific, @infinitybioinc, @cdi_labs, and Theriome, but we saved some extra in case we come across additional testing.
We also collected a ton of other data, like HRV, symptoms, lactate, HR, BP, etc. @immunofever's team from MIT was also there demoing nailfold capillaroscopy, WAVi EEG, and Right Eye.
We want to get as many eyes as possible on our data and have as much analysis as possible done on our samples, so please reach out if you're interested in helping.
#InnovationInn
ChronicleBio retweeted
I was so proud of our team yesterday and grateful for everyone supporting us.
Our team had 3 time-critical issues hit us at the same time. ALL of the samples we had collected over 2 days were in danger. Everyone stayed calm and focused and jumped into action.
Thanks to @dibidave and @imyoohealth for being on top of things, watching the tracking for the package we were supposed to get out that day with overnight shipping. We thought it went out that morning, but it was still sitting on the counter when I noticed their messages at like 6pm. I dropped it off with 5 minutes to spare.
Thanks to @Drewhywhywhy's doctor for getting us space in his hospital's -80 freezer for 180 samples from the first two days.
Thanks to Alain Moreau and his team for getting us dry ice and space in one of his -80 freezers.
Thanks to @rohit0logy for hopping on a call with us to tell us how to process the samples for @ChronicleBioAI.
#InnovationInn
1/Yesterday we had a huge scare. Our -80 freezer broke.
I (@IsabelRamirezRD ) think that’s why my PEM was worse.
Our host Marie and @doc4care sprung to action and drove the specimens to a doctor friend of hers at his hospital
ChronicleBio retweeted
"You know, when I was at OpenAI, I said I think if AI accomplishes everything but doesn’t cure disease, that would be a very sad state of affairs."
In Fidji's first interview since leaving OpenAI, she tells me about her company ChronicleBio.
🧵
fortune.com/2026/08/03/fidji…
ChronicleBio retweeted
Former OpenAI exec @fidjissimo plans to cure POTS with AI and 3,500 vials of blood.
@EmilyForlini joined @Ellie_Austin_ and #FortuneDaily to break down Simo's plan to cure the disease with AI. bit.ly/3Rst3Ag
ChronicleBio retweeted
Driven by her commitment to patients living with complex chronic disorders, @fidjissimo continues to push research for complex chronic disorders forward.
@ChronicleBioAI to help uncover the biology underlying these diseases, opening the door to stronger testing, endotyping and better treatments.
While AI gives me a lot of hope to find cures for complex chronic conditions like mine, this potential will only be realized if we get enough biological data to understand the mechanisms of these conditions. That’s what we’re trying to do at @ChronicleBioAI:
fortune.com/2026/08/03/fidji…
ChronicleBio retweeted
To harness the true power of AI to solve disease… (spoiler) we need data.
The data doesn’t / didn’t exist so we had to build a scalable physical ecosystem to generate it.
With our own data + ai infrastructure + brilliant scientists we can resolve clumsy disease labels into distinct known biological mechanisms and begin to discover new ones.
When we understand biology at an individual level we can bring precision tx programs to millions desperately seeking answers.
Thanks Fortune for covering what we’re building @ChronicleBioAI.
While AI gives me a lot of hope to find cures for complex chronic conditions like mine, this potential will only be realized if we get enough biological data to understand the mechanisms of these conditions. That’s what we’re trying to do at @ChronicleBioAI:
fortune.com/2026/08/03/fidji…
ChronicleBio retweeted
Replying to @fidjissimo @ChronicleBioAI
We’re casting a deep net across patients living with these devastating conditions. Every data point brings us closer to answers. I dream of the day when biology, not an ICD code, guides treatment. Thank you to everyone who has participated and to those who will join this journey
ChronicleBio retweeted
While AI gives me a lot of hope to find cures for complex chronic conditions like mine, this potential will only be realized if we get enough biological data to understand the mechanisms of these conditions. That’s what we’re trying to do at @ChronicleBioAI:
fortune.com/2026/08/03/fidji…





















